BioMedion AG Acquires the Compliance Division of arivis AG

BioMedion AG announces the acquisition of arivis AG, a provider of regulatory software and biomedical 3D and big picture data software solutions

FREMONT, CA: A global Compliance Management Software company offering managed content and raw data management solutions for the life science industry, BioMedion AG  announces the acquisition of arivis AG, a provider of regulatory software and biomedical 3D and big picture data software solutions, from the Compliance Division.

BioMedion was founded in 2000 and provided a suite of software utilized in every area of good practice (GxP) where quality standards and regulations are essential. The organization currently serves 115 clients in 15 countries worldwide.

The company has acquired the cloud-based arivis5D content platform that provides users in the pharmaceutical, medical, food, and crop sciences industries a comprehensive, integrated, and computerized approach. BioMedion would have a modern operating system for managed applications operating efficiently on a single platform in controlled environments with the convergence of both parties' technologies.

Following the purchase, neuronOS will be rebranded as the arivis5D content network. By adding new technologies to control multiple digital content types, including instrument data (e.g., scientific images) and digital formats, neuronOS would improve the company's GxP consistency, enforcement, and archiving solutions.

"We are excited to announce the acquisition of the Compliance Division of arivis as we take a major step forward in strengthening our compliance competencies and market position not only in Europe, but also in North America and Asia," said Klaus Pflum, Chairman of the BioMedions Supervisory Board. Matthias Wiedenfels, who facilitated the deal and joins the management board as Chief Corporate Development Officer, added, "The arivis Compliance Division is a perfect match to BioMedions activities in providing next generation software to our customers in highly-regulated industries."

"This strategic acquisition solidifies our position as an integrated software provider with cutting-edge solutions, to leverage innovation amongst the entire life sciences life cycle," said Thorsten Dunker, Chief Operating Officer (COO) of BioMedion.

UniCredit Corporate & Investment Banking operated as a financial analyst. The legal advisors were Osborne Clarke and Ashurst LLP. The parties have agreed that no further financial details of the deal will be disclosed.